Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. (åpner nytt vindu)

CRASH-3 Trial Collaborators

Kilde‎: Lancet 2019;394(10210):1713-23.

Arkiv‎: PubMed 31623894

DOI‎: 10.1016/S0140-6736(19)32233-0

https://www.ncbi.nlm.nih.gov/pubmed/31623894 (åpner nytt vindu)

Alternatives to allogeneic platelet transfusion. (åpner nytt vindu)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Kilde‎: Br J Haematol 2016;175(3):381-92.

Arkiv‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (åpner nytt vindu)

Tranexamic acid: less bleeding and less thrombosis? (åpner nytt vindu)

Godier A, Roberts I, Hunt BJ.

Kilde‎: Crit Care 2012;16(3):135.

Arkiv‎: PubMed 22748073

DOI‎: 10.1186/cc11374

https://www.ncbi.nlm.nih.gov/pubmed/22748073 (åpner nytt vindu)

Tranexamic acid for reducing mortality in emergency and urgent surgery. (åpner nytt vindu)

Perel P, Ker K, Morales Uribe CH, Roberts I

Kilde‎: Cochrane Database Syst Rev 2013;(1):CD010245.

Arkiv‎: PubMed 23440847

DOI‎: 10.1002/14651858.CD010245.pub2

https://www.ncbi.nlm.nih.gov/pubmed/23440847 (åpner nytt vindu)

The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. (åpner nytt vindu)

Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T; CRASH-2 collaborators.

Kilde‎: Lancet 2011;377(9771):1096-101, 1101.e1-2.

Arkiv‎: PubMed 21439633

DOI‎: 10.1016/S0140-6736(11)60278-X

https://www.ncbi.nlm.nih.gov/pubmed/21439633 (åpner nytt vindu)

Antifibrinolytic drugs for acute traumatic injury. (åpner nytt vindu)

Roberts I, Shakur H, Ker K, Coats T; CRASH‐2 Trial collaborators.

Kilde‎: Cochrane Database Syst Rev 2011;(1):CD004896.

Arkiv‎: PubMed 21249666

DOI‎: 10.1002/14651858.CD004896.pub3

https://www.ncbi.nlm.nih.gov/pubmed/21249666 (åpner nytt vindu)

Use of tranexamic acid to reduce bleeding in burns surgery. (åpner nytt vindu)

Tang YM, Chapman TW, Brooks P

Kilde‎: J Plast Reconstr Aesthet Surg 2012;65(5):684-6.

Arkiv‎: PubMed 21983540

DOI‎: 10.1016/j.bjps.2011.09.028

https://www.ncbi.nlm.nih.gov/pubmed/21983540 (åpner nytt vindu)

Tranexamic acid reduced blood transfusions in acute burn surgery: a retrospective case-controlled trial. (åpner nytt vindu)

Tapking C, Hundeshagen G, Kirchner M, Fischer S, Kneser U, Bliesener B

Kilde‎: Burns. 2022;48(3):522-28.

Arkiv‎: PubMed 35339324

DOI‎: 10.1016/j.burns.2022.03.002

https://pubmed.ncbi.nlm.nih.gov/35339324/ (åpner nytt vindu)

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery. (åpner nytt vindu)

Barua A, Rao VP, Ramesh B, Barua B, El-Shafei H.

Kilde‎: J Blood Med 2011;2:131-4.

Arkiv‎: PubMed 22287872

DOI‎: 10.2147/JBM.S21609

https://www.ncbi.nlm.nih.gov/pubmed/22287872 (åpner nytt vindu)

The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. (åpner nytt vindu)

Boffard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, Warren B; NovoSeven Trauma Study Group.

Kilde‎: Transfusion 2009;49 Suppl 5:240S-7S.

Arkiv‎: PubMed 19954486

DOI‎: 10.1111/j.1537-2995.2008.01987.x

https://www.ncbi.nlm.nih.gov/pubmed/19954486 (åpner nytt vindu)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (åpner nytt vindu)

Fries D

Kilde‎: Transfusion 2013;53 Suppl 1:91S-5S.

Arkiv‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (åpner nytt vindu)

A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. (åpner nytt vindu)

Haan J, Scalea T

Kilde‎: Am Surg 2005;71(5):414-5.

Arkiv‎: PubMed 15986972

https://www.ncbi.nlm.nih.gov/pubmed/15986972 (åpner nytt vindu)

Results of the control trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. (åpner nytt vindu)

Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent JL, Tortella BJ, Dimsits J, Bouillon B; CONTROL Study Group.

Kilde‎: J Trauma 2010;69(3):489-500.

Arkiv‎: PubMed 20838118

DOI‎: 10.1097/TA.0b013e3181edf36e

https://www.ncbi.nlm.nih.gov/pubmed/20838118 (åpner nytt vindu)

Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. (åpner nytt vindu)

Hsia CC, Chin-Yee IH, McAlister VC.

Kilde‎: Ann Surg 2008;248(1):61-8.

Arkiv‎: PubMed 18580208

DOI‎: 10.1097/SLA.0b013e318176c4ec

https://www.ncbi.nlm.nih.gov/pubmed/18580208 (åpner nytt vindu)

Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases. (åpner nytt vindu)

Johansson PI, Eriksen K, Alsbjørn B

Kilde‎: J Trauma 2006;61(4):1016-8.

Arkiv‎: PubMed 17033583

DOI‎: 10.1097/01.ta.0000239261.48022.f1

https://www.ncbi.nlm.nih.gov/pubmed/17033583 (åpner nytt vindu)

Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. (åpner nytt vindu)

Kandane-Rathnayake RK, Isbister JP, Zatta AJ, Aoki NJ, Cameron P, Phillips LE; Australian and New Zealand Haemostasis Registry Steering Committee

Kilde‎: ANZ J Surg 2013;83(3):155-60.

Arkiv‎: PubMed 23035873

DOI‎: 10.1111/j.1445-2197.2012.06285.x

https://www.ncbi.nlm.nih.gov/pubmed/23035873 (åpner nytt vindu)

Recombinant factor VIIa in trauma patients with the 'triad of death.' (åpner nytt vindu)

Mitra B, Cameron PA, Parr MJ, Phillips L.

Kilde‎: Injury 2012;43(9):1409-14.

Arkiv‎: PubMed 21345431

DOI‎: 10.1016/j.injury.2011.01.033

https://www.ncbi.nlm.nih.gov/pubmed/21345431 (åpner nytt vindu)

Low-dose recombinant factor VIIa for trauma patients with coagulopathy. (åpner nytt vindu)

Stein DM, Dutton RP, Hess JR, Scalea TM.

Kilde‎: Injury 2008;39(9):1054-61.

Arkiv‎: PubMed 18656871

DOI‎: 10.1016/j.injury.2008.03.032

https://www.ncbi.nlm.nih.gov/pubmed/18656871 (åpner nytt vindu)

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (åpner nytt vindu)

Tanaka KA, Waly AA, Cooper WA, Levy JH.

Kilde‎: Anesthesiology 2003;98(6):1513-5.

Arkiv‎: PubMed 12766668

https://www.ncbi.nlm.nih.gov/pubmed/12766668 (åpner nytt vindu)

Alternatives to allogeneic platelet transfusion. (åpner nytt vindu)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Kilde‎: Br J Haematol 2016;175(3):381-92.

Arkiv‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (åpner nytt vindu)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (åpner nytt vindu)

Fries D

Kilde‎: Transfusion 2013;53 Suppl 1:91S-5S.

Arkiv‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (åpner nytt vindu)

Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor of postoperative bleeding after cardiac surgery with cardiopulmonary bypass. (åpner nytt vindu)

Kindo M, Hoang Minh T, Gerelli S, Perrier S, Meyer N, Schaeffer M, Bentz J, Announe T, Mommerot A, Collange O, Pottecher J, Cristinar M, Thiranos JC, Gros H, Mertes PM, Billaud P, Mazzucotelli JP

Kilde‎: Thromb Res 2014;134(2):360-8.

Arkiv‎: PubMed 24857189

DOI‎: 10.1016/j.thromres.2014.05.008

https://www.ncbi.nlm.nih.gov/pubmed/24857189 (åpner nytt vindu)

Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. (åpner nytt vindu)

Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B

Kilde‎: Br J Haematol 2013;160(2):228-36.

Arkiv‎: PubMed 23151086

DOI‎: 10.1111/bjh.12118

https://www.ncbi.nlm.nih.gov/pubmed/23151086 (åpner nytt vindu)

Strategies to reduce the use of blood products: a European perspective. (åpner nytt vindu)

Theusinger OM, Felix C, Spahn DR.

Kilde‎: Curr Opin Anaesthesiol 2012;25(1):59-65.

Arkiv‎: PubMed 22113184

DOI‎: 10.1097/ACO.0b013e32834dec98

https://www.ncbi.nlm.nih.gov/pubmed/22113184 (åpner nytt vindu)

Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. (åpner nytt vindu)

Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E, Fochi O, Maj G, Calabrò MG, Ranucci M, Zangrillo A

Kilde‎: Anesthesiology 2008;109(6):1063-76.

Arkiv‎: PubMed 19034103

DOI‎: 10.1097/ALN.0b013e31818db18b

https://www.ncbi.nlm.nih.gov/pubmed/19034103 (åpner nytt vindu)

Alternatives to allogeneic platelet transfusion. (åpner nytt vindu)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Kilde‎: Br J Haematol 2016;175(3):381-92.

Arkiv‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (åpner nytt vindu)

Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. (åpner nytt vindu)

Svensson PJ, Bergqvist PB, Juul KV, Berntorp E

Kilde‎: Blood Rev 2014;28(3):95-102.

Arkiv‎: PubMed 24703870

DOI‎: 10.1016/j.blre.2014.03.001

https://www.ncbi.nlm.nih.gov/pubmed/24703870 (åpner nytt vindu)

Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. (åpner nytt vindu)

Alperin JB

Kilde‎: JAMA 1987;258(14):1916-9.

Arkiv‎: PubMed 3656602

DOI‎: 10.1001/jama.1987.03400140078028

https://www.ncbi.nlm.nih.gov/pubmed/3656602 (åpner nytt vindu)

Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. (åpner nytt vindu)

Crowther MA, McDonald E, Johnston M, Cook D

Kilde‎: Blood Coagul Fibrinolysis 2002;13(1):49-52.

Arkiv‎: PubMed 11994567

DOI‎: 10.1097/00001721-200201000-00007

https://www.ncbi.nlm.nih.gov/pubmed/11994567 (åpner nytt vindu)

The use of fibrin sealant in burn operations. (åpner nytt vindu)

Foster K

Kilde‎: Surgery 2007;142(4 Suppl):S50-4.

Arkiv‎: PubMed 18019939

DOI‎: 10.1016/j.surg.2007.06.026

https://www.ncbi.nlm.nih.gov/pubmed/18019939 (åpner nytt vindu)

Use of fibrin sealant in thermal injury. (åpner nytt vindu)

McGill V, Kowal-Vern A, Lee M, Greenhalgh D, Gomperts E, Bray G, Gamelli R

Kilde‎: J Burn Care Rehabil 1997;18(5):429-34.

Arkiv‎: PubMed 9313125

DOI‎: 10.1097/00004630-199709000-00011

https://www.ncbi.nlm.nih.gov/pubmed/9313125 (åpner nytt vindu)

Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. (åpner nytt vindu)

Schaden E, Kimberger O, Kraincuk P, Baron DM, Metnitz PG, Kozek-Langenecker S

Kilde‎: Br J Anaesth 2012;109(3):376-81.

Arkiv‎: PubMed 22719014

DOI‎: 10.1093/bja/aes186

https://www.ncbi.nlm.nih.gov/pubmed/22719014 (åpner nytt vindu)

Transfusion in trauma: why and how should we change our current practice? (åpner nytt vindu)

Theusinger OM, Spahn DR, Ganter MT.

Kilde‎: Curr Opin Anaesthesiol 2009;22(2):305-12.

Arkiv‎: PubMed 19390257

DOI‎: 10.1097/ACO.0b013e3283212c7c

https://www.ncbi.nlm.nih.gov/pubmed/19390257 (åpner nytt vindu)

Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. (åpner nytt vindu)

Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J

Kilde‎: Health Technol Assess 2015;19(58):1-228.

Arkiv‎: PubMed 26215747

DOI‎: 10.3310/hta19580

https://www.ncbi.nlm.nih.gov/pubmed/26215747 (åpner nytt vindu)